Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphomaSami Mamand(University of Leicester), Simon D. Wagner(University of Leicester)Scientific ReportsSeptember 17, 201810.1038/s41598-018-32634-5Cited by 37SaveCiteExport RISWatch citationsRelated PapersCirculating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin’s lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma|PLoS ONE|2018|23Structural and diffusion weighted MRI demonstrates responses to ibrutinib in a mouse model of follicular helper (Tfh) T-cell lymphoma|PLoS ONE|2019|5